Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status

Table 1 Evaluation of Her-2/neu gene status using chromogenic in situ hybridization

Amplification	Her-2/neu gene status
High-level	>10 copies or large cluster of amplicon per nucleus in >50% of cancer cells
Low-level	6–10 copies or small cluster of amplicon per nucleus in >50% of cancer cells^a
None	1–5 copies per nucleus of cancer cells^b

^aVerify gene amplification or chromosome 17 aneuploidy with SPOT-Light Chromosome 17 Centromeric Probe. ^bIf 3–5 copies per nucleus, verify chromosomal aneuploidy with SPOT-Light Chromosome 17 Centromeric Probe.

ISSN: 1465-542X